Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SRTA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsStrata Critical Medical shareholders approve executive pay despite 17% opposition at annual meeting
Filed June 3, 2026 · Period ending May 28, 2026 · ~1 min read
Key Changes
-
medium
Shareholders approved executive compensation on advisory vote with 38.5M for and 8.0M against, representing 17% opposition—a notable level of dissent that may signal concerns about pay structure or levels.
Item 5.07 verify on EDGAR → -
low
Class II directors William Heyburn and Andrew Lauck elected to serve until 2029, though Lauck received 7.0M withheld votes (15% of votes cast) compared to Heyburn's 505K withheld.
Item 5.07 verify on EDGAR → -
low
Shareholders ratified Deloitte & Touche LLP as independent auditor for 2026 with 59M votes for and minimal opposition, a routine annual approval.
Item 5.07 verify on EDGAR →
Summary
Strata Critical Medical held its 2026 annual meeting on May 28, with shareholders voting on standard governance matters. The most notable result was the say-on-pay vote, where executive compensation received approval but with 17% of votes cast in opposition—a level that suggests meaningful shareholder concern about how executives are paid. While advisory and non-binding, this level of dissent often prompts boards to review compensation practices.
The director elections showed similar patterns, with Class II nominee Andrew Lauck receiving 15% withheld votes compared to just 1% for William Heyburn, though both were elected to three-year terms. The auditor ratification passed with overwhelming support. For retail investors, the key item to watch is whether management or the compensation committee addresses shareholder concerns in upcoming proxy materials or earnings calls, particularly regarding executive pay structure or performance metrics.
Section-by-Section Diff
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Strata Critical Medical held its 2026 annual meeting, electing two Class II directors, ratifying Deloitte as auditor, and approving executive compensation.
Added in current filing · verify on EDGAR →
The Company's stockholders approved, on an advisory, non-binding basis, the compensation of the Company's named executive officers (the "Say-on-Pay" vote).
Shareholders approved executive compensation on an advisory basis with 38,497,962 votes for, 8,022,682 against, and 35,679 abstentions. While the vote passed, approximately 17% of votes cast were against the compensation plan, indicating some shareholder dissatisfaction with executive pay levels or structure.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR →
The Company’s stockholders elected the two (2) Class II directors listed below to the Board of Directors of the Company to hold office until the 2029 annual meeting of stockholders and until their respective successors have been duly elected and qualified.
Shareholders elected William A. Heyburn and Andrew Lauck as Class II directors to serve until 2029. Heyburn received 46,050,902 votes for with 505,421 withheld, while Lauck received 39,525,159 votes for with 7,031,164 withheld. Both directors were elected despite Lauck receiving notably more withheld votes.
Added in current filing · verify on EDGAR →
The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Shareholders ratified Deloitte & Touche LLP as the independent auditor for fiscal year 2026 with 58,946,832 votes for, 65,815 against, and 231,172 abstentions. This is a routine annual vote confirming the audit committee's selection of the external auditor.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 4, 2026 · How we verify